Cyclophosphamide in scleroderma lung disease

Steer, H.
October 2006
Thorax;Oct2006, Vol. 61 Issue 10, p908
Academic Journal
The article reports on a multicenter controlled trial which evaluated the effectiveness of oral cyclophosphamide in patients with scleroderma who had restrictive lung function, exertional dyspnea and evidence of active alveolitis. Patients with more severe fibrosis at baseline had the greatest benefit in forced vital capacity. Adverse events were more common in the cyclophosphamide group, including leucopenia and neutropenia.


Related Articles

  • Sildenafil Therapy and Exercise Tolerance in Idiopathic Pulmonary Fibrosis. Jackson, Robert M.; Glassberg, Marilyn K.; Ramos, Carol F.; Bejarano, Pablo A.; Butrous, Ghazwan; Gómez-Marín, Orlando // Lung;Apr2010, Vol. 188 Issue 2, p115 

    Idiopathic pulmonary fibrosis (IPF) is a form of idiopathic interstitial pneumonia characterized by temporally and spatially heterogeneous fibroblast proliferation and poor prognosis. No therapies have been shown in randomized clinical trials (RCT) to influence survival. Twenty-nine subjects...

  • MUC5B: a good target for future therapy in pulmonary fibrosis? Mahida, Rahul; Turner, Alice M. // Thorax;May2013, Vol. 68 Issue 5, p401 

    The article reflects the role of MUC5B gene in the treatment of idiopathic pulmonary fibrosis (IPF). It states that the dysregulation of MUC5B gene expression in the lung may be the cause of pathogenesis of pulmonary fibrosis. It further states that an excess of MUC5B impairs mucosal host...

  • Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Nakamura, K.; Yamaguchi, T.; Ishihara, T.; Sudo, K.; Kato, H.; Saisho, H. // British Journal of Cancer;6/5/2006, Vol. 94 Issue 11, p1575 

    We conducted a phase II trial of gemcitabine with S-1, oral fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, to evaluate the activity and toxicity of such a combination in metastatic pancreatic cancer (MPC) patients....

  • A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis. Clark, M.; Cooper, B.; Singh, S.; Cooper, M.; Carr, A.; Hubbard, R. // Thorax;Jun2001, Vol. 56 Issue 6, p482 

    Background: A survey of overnight oximetry was conducted to estimate the prevalence of nocturnal hypoxaemia in patients with cryptogenic fibrosing alveolitis and to establish whether nocturnal hypoxaemia is related to quality of life. Methods: All patients with...

  • Medical Research Council dyspnea scale does not relate to fibroblast foci profusion in IPF. Triantafillidou, Christina; Manali, Effrosyni D.; Magkou, Christina; Sotiropoulou, Christina; Kolilekas, Likurgos F.; Kagouridis, Konstantinos; Rontogianni, Dimitra; Papiris, Spyros A. // Diagnostic Pathology;2011, Vol. 6 Issue 1, p28 

    Background: In Idiopathic pulmonary fibrosis (IPF) irreversibly progressive fibrosing parenchymal damage, leads to defects in mechanics and gas exchange, manifesting with disabling exertional dyspnea. Previous studies have shown a relationship between fibroblast foci (FF) profusion and severity...

  • A Preliminary Study of Long-Term Treatment with Interferon Gamma-1b and Low-Dose Prednisolone in Patients with Idiopathic Pulmonary Fibrosis. Ziesche, Rolf; Hofbauer, Elisabeth; Wittmann, Karin; Petkov, Ventzislav; Block, Lutz-Henning // New England Journal of Medicine;10/21/99, Vol. 341 Issue 17, p1264 

    Background: Patients with idiopathic pulmonary fibrosis have progressive scarring of the lung and usually die within four to five years after symptoms develop. Treatment with oral glucocorticoids is often ineffective. We conducted an open, randomized trial of treatment with a combination of...

  • Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality. Edey, Anthony J.; Devaraj, Anand A.; Barker, Robert P.; Nicholson, Andrew G.; Wells, Athol U.; Hansell, David M. // European Radiology;Aug2011, Vol. 21 Issue 8, p1586 

    Objectives: The study aims were to identify CT features that predict outcome of fibrotic idiopathic interstitial pneumonia (IIP) when information from lung biopsy data is unavailable. Methods: HRCTs of 146 consecutive patients presenting with fibrotic IIP were studied. Visual estimates were made...

  • Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Yiannopoulos, George; Pastromas, Vassilios; Antonopoulos, Ioannis; Katsiberis, George; Kalliolias, George; Liossis, Stamatis-Nick; Andonopoulos, Andrew // Rheumatology International;Feb2007, Vol. 27 Issue 4, p357 

    The purpose of the study was to examine prospectively the efficacy and safety of the combination of intravenous pulses of cyclophosphamide and methylprednizolone, in the treatment of scleroderma lung disease. Thirteen patients were treated with the above combination for up to 24 months. Prior to...

  • Cyclophosphamide improves QOL in scleroderma lung disorder.  // PharmacoEconomics & Outcomes News;6/30/2007, Issue 531, p10 

    The article reports on a study which found that cyclophosphamide therapy improves health-related quality of life in patients with systemic scleroderma-related interstitial lung disorder. Participants in the study were randomized to receive cyclophosphamide or placebo for 12 months. The Health...


Read the Article


Sign out of this library

Other Topics